The latest news from Limbus AI.
September 18, 2020
Limbus AI receives FDA clearance for Limbus Contour
Limbus AI announces 510(k) clearance from the U.S. Food and Drug Administration for Limbus Contour, the company’s artificial intelligence (AI) powered automatic contouring software. Limbus AI is focused on the development of products designed to improve efficiency in cancer diagnosis, treatment, and follow up. Their flagship product, Limbus Contour, is backed by comprehensive research and produces clinical grade contours that are revolutionizing the speed of planning radiation therapy treatments.
“With Limbus Contour, clinicians have significantly reduced contouring time, allowing them to dedicate more time to direct patient care.
We believe our product will set the standard for AI based automatic contouring and dramatically improve the productivity in any radiotherapy department. The product shows expert level performance, is simple to use and integrates with any treatment planning platform.” - Dr. Joshua Giambattista, Medical Lead, Limbus AI.
510(k) clearance for Contour is a significant milestone for Limbus AI. The company will now be seeking to expand into the US market while continuing the development of additional AI contouring products. With an established network of international clinical partners and a growing list of peer reviewed research publications, Limbus AI is well positioned to develop, validate and market test new AI based products for cancer care.
June 28, 2019
Limbus AI discusses automatic contouring with ProKnow Systems
In this episode of The Fraction, Ben talks to three of the founders of Limbus AI, a Canadian startup company specializing in machine learning automation to produce anatomy contours.
This episode includes live demonstrations of their software in action, where we use the ProKnow Contouring Accuracy Program to compare their automated contours to physician experts as well as to populations of radiation therapy professionals.